FAST NEWS: Gracell shareholders approve merger with AstraZeneca
The latest: Gracell Biotechnologies Inc. (GRCL.US) announced Tuesday that its shareholders approved the company’s sale to AstraZeneca (AZN.L) at an extraordinary general meeting on Feb. 19. Looking up: Gracell’s merger with…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant Key Takeaways: AstraZeneca…
CHINA BULLETIN: China-India Tensions Flare with New Arrests
In this week’s issue new China-India tensions, BYD overtakes Tesla, and Boeing emerges from the China doghouse. On a scale of 1 to 100, we give the week a 55…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
PODCAST: European businesses glum on China, and AstraZeneca weighs spin-off for Chinese unit
The latest annual survey by the EU Chamber of Commerce in China shows revenue fell for more European businesses’ China operations last year. Is this a watershed moment for China’s economy, showing the days of western enthusiasm for investing in the country will never return to pre-covid levels? And AstraZeneca has become the latest major company to weigh a potential spinoff of its China unit. Is this the beginning of a trend?
CHINA BULLETIN: No Fun for European Firms in China
In this week’s issue European businesses get glum on China, consumers write off June 18 shopping fest and a three-week stock rally crashes. On a scale of 1 to 100, we give the week a 40 for offshore-listed China stocks.
Recent Articles
RELATED ARTICLES
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US
- CHINA BULLETIN: China-India Tensions Flare with New Arrests
- CHINA BULLETIN: PMI Readings Signal Strong End to 2023
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- ProfoundBio discovers the joys of having a wealthy owner
- CHINA BULLETIN: No Fun for European Firms in China
- PODCAST: European businesses glum on China, and AstraZeneca weighs spin-off for Chinese unit
